Recombinant Human MYLK2, N-His

Description of Recombinant Human MYLK2, N-His

Introduction

Recombinant Human MYLK2 is a protein that plays a crucial role in regulating muscle contraction. It is a recombinant protein, meaning it is produced through genetic engineering techniques. In this article, we will discuss the structure, activity, and application of Recombinant Human MYLK2.

Structure of Recombinant Human MYLK2

Recombinant Human MYLK2 is a member of the myosin light chain kinase (MLCK) family of proteins. It is encoded by the MYLK2 gene and is composed of 1,080 amino acids. The protein has a molecular weight of approximately 123 kDa.

The structure of Recombinant Human MYLK2 is characterized by several functional domains. These include the N-terminal catalytic domain, the central calmodulin-binding domain, and the C-terminal regulatory domain. The catalytic domain is responsible for the kinase activity of MYLK2, while the calmodulin-binding domain is involved in the regulation of its activity.

Activity of Recombinant Human MYLK2

The primary function of Recombinant Human MYLK2 is to phosphorylate myosin light chains (MLCs), which are essential for muscle contraction. This process is regulated by the binding of calcium ions to the calmodulin-binding domain of MYLK2. When calcium ions are present, they bind to calmodulin, which in turn activates MYLK2. This leads to the phosphorylation of MLCs, resulting in muscle contraction.

In addition to its role in muscle contraction, Recombinant Human MYLK2 has been found to have other activities as well. It has been shown to play a role in cell migration, cell proliferation, and cell survival. These activities are mediated through the regulation of various signaling pathways, including the RhoA/ROCK pathway and the PI3K/Akt pathway.

Application of Recombinant Human MYLK2

Recombinant Human MYLK2 has various applications in both research and therapeutic settings. One of its primary uses is in the study of muscle contraction and its regulation. Recombinant Human MYLK2 can be used to investigate the role of MYLK2 in different types of muscle cells and tissues.

In addition, Recombinant Human MYLK2 has potential therapeutic applications. It has been found to be overexpressed in certain types of cancer, such as breast cancer and lung cancer. This makes it a potential target for cancer treatment. Inhibitors of MYLK2 have been developed and are being studied for their effectiveness in cancer treatment.

Furthermore, Recombinant Human MYLK2 has been shown to play a role in cardiovascular diseases. It has been found to be involved in the regulation of blood vessel contraction, which can impact blood pressure and blood flow. Therefore, targeting MYLK2 may have potential therapeutic benefits for cardiovascular diseases.

Conclusion

In summary, Recombinant Human MYLK2 is a crucial protein involved in regulating muscle contraction. It is composed of several functional domains, including the catalytic domain, the calmodulin-binding domain, and the regulatory domain. Its activity is regulated by calcium ions, and it has been found to have various roles in cell signaling and disease processes. With its diverse applications in research and potential therapeutic benefits, Recombinant Human MYLK2 is a promising protein for further study and development.